Back

SGLT-2 inhibitors are associated with lower rates of mortality following myocardial infarction in patients with type 2 diabetes - A SWEDEHEART observational study

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Hans Christian Rosen

Lund (Sweden)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
Professor G. Montalescot (Paris, FR)
Slides Video
Presentation thumbnail
Incidence and pattern of repeat coronary revascularizations in patients with acute coronary syndromes treated with ticagrelor or prasugrel
Doctor A. Aytekin (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Current concepts of treatment for left ventricular thrombus: A sys-tematic meta-analysis comparing direct oral anticoagulants versus vitamin K-antagonists
Mr T. Seiler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Abbreviated versus standard dual antiplatelet therapy time after PCI in high bleeding risk patients with acute coronary syndrome - a report from the SWEDEHEART registry
Mr A. Haakansson (Lund, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes
thumbnail
Congress Presentation
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population
thumbnail
Congress Presentation
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources